| 摘要 |
PROBLEM TO BE SOLVED: To provide a novel CD37 antagonist for the treatment of a B cell malignancy and other disorder which responds to the depletion of a CD37 positive B cell.SOLUTION: A murine monoclonal antibody binding to human CD37 is defined by a)i) a variable heavy chain comprising a specific amino acid sequence, and ii) a variable light chain comprising a specific amino acid sequence. A chimeric or humanized antibody is derived from a humanized antibody defined by b)i) a complementarity determining region (CDR) contained within the variable heavy chain shown in the specific amino acid, ii) a CDR contained within the variable light chain as shown in the specific amino acid, iii) a framework supporting said CDRs that are derived from a human antibody, and iv) constant heavy and light chains that are from a human antibody. |
